Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.
Alsaed B, Lin L, Son J, Li J, Smolander J, Lopez T, Eser PÖ, Ogino A, Ambrogio C, Eum Y, Thai T, Wang H, Sutinen E, Mutanen H, Duàn H, Bobik N, Borenius K, Feng WW, Nabet B, Mustjoki S, Laaksonen S, Eschle BK, Poitras MJ, Barbie D, Ilonen I, Gokhale P, Jänne PA, Haikala HM. Alsaed B, et al. Among authors: barbie d. Nat Commun. 2025 Jan 2;16(1):28. doi: 10.1038/s41467-024-55378-5. Nat Commun. 2025. PMID: 39747003 Free PMC article.
RNA sensing induced by chromosome missegregation augments anti-tumor immunity.
Sasaki N, Homme M, Murayama T, Osaki T, Tenma T, An T, Takegami Y, Tani T, Gedeon PC, Kobayashi Y, Cañadas I, Barbie DA, Yao R, Kitajima S. Sasaki N, et al. Among authors: barbie da. Mol Cell. 2024 Dec 10:S1097-2765(24)00950-X. doi: 10.1016/j.molcel.2024.11.025. Online ahead of print. Mol Cell. 2024. PMID: 39706184
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Sehgal K, Pappa T, Shin KY, Schiantarelli J, Liu M, Ricker C, Besson NR, Jones SM, Welsh EL, Pfaff KL, Barletta JA, Park J, Reardon B, Doherty GM, Alexander EK, Rodig SJ, Barbie DA, O'Neill A, Van Allen E, Haddad RI, Lorch JH. Sehgal K, et al. Among authors: barbie da. JAMA Oncol. 2024 Dec 1;10(12):1663-1671. doi: 10.1001/jamaoncol.2024.4019. JAMA Oncol. 2024. PMID: 39446365 Clinical Trial.
miR126-mediated impaired vascular integrity in Rett syndrome.
Osaki T, Wan Z, Haratani K, Jin Y, Campisi M, Barbie DA, Kamm R, Sur M. Osaki T, et al. Among authors: barbie da. bioRxiv [Preprint]. 2024 Oct 13:2024.10.11.617929. doi: 10.1101/2024.10.11.617929. bioRxiv. 2024. PMID: 39415995 Free PMC article. Preprint.
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution.
Schade AE, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Gardner A, Loi P, Xu Y, Nguyen VTM, Mastellone GM, Pilla NF, Watanabe M, Ota K, Davis RA, Mattioli K, Xiang D, Zoeller JJ, Lin JR, Morganti S, Garrido-Castro AC, Tolaney SM, Li Z, Barbie DA, Sorger PK, Helin K, Santagata S, Knott SRV, Cichowski K. Schade AE, et al. Among authors: barbie da. Nature. 2024 Nov;635(8039):755-763. doi: 10.1038/s41586-024-08031-6. Epub 2024 Oct 9. Nature. 2024. PMID: 39385030 Free PMC article.
Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses.
Yang S, Sheffer M, Kaplan IE, Wang Z, Tarannum M, Dinh K, Abdulhamid Y, Bobilev E, Shapiro R, Porter R, Soiffer R, Ritz J, Koreth J, Wei Y, Chen P, Zhang K, Márquez-Pellegrin V, Bonanno S, Joshi N, Guan M, Yang M, Li D, Bellini C, Liu F, Chen J, Wu CJ, Barbie D, Li J, Romee R. Yang S, et al. Among authors: barbie d. Nat Biotechnol. 2024 Oct 4. doi: 10.1038/s41587-024-02418-6. Online ahead of print. Nat Biotechnol. 2024. PMID: 39367093
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer.
Murayama T, Mahadevan NR, Meador CB, Ivanova EV, Pan Y, Knelson EH, Tani T, Nakayama J, Ma X, Thai TC, Hung YP, Kim W, Watanabe H, Cai KQ, Hata AN, Paweletz CP, Barbie DA, Cañadas I. Murayama T, et al. Among authors: barbie da. Cancer Res Commun. 2024 Sep 1;4(9):2399-2414. doi: 10.1158/2767-9764.CRC-24-0360. Cancer Res Commun. 2024. PMID: 39177280 Free PMC article.
Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R.
Nguyen HT, Kan EL, Humayun M, Gurvich N, Offeddu GS, Wan Z, Coughlin MF, Renteria DC, Loew A, Wilson S, Zhang C, Vu V, Lee SWL, Tan SL, Barbie D, Hsu J, Gillrie MR, Kamm RD. Nguyen HT, et al. Among authors: barbie d. Biomaterials. 2025 Jan;312:122731. doi: 10.1016/j.biomaterials.2024.122731. Epub 2024 Jul 30. Biomaterials. 2025. PMID: 39153324
130 results